Effects of Treatment of Coronavirus Disease 2019 With Convalescent Plasma in 25 B-Cell-Depleted Patients

Arvind Gharbharan; Corine H GeurtsvanKessel; Carlijn C E Jordans; Marc Blaauw; Marjolein van der Klift; Robert-Jan Hassing; Marijn Smits-Zwinkels; Maaike Meertens; Ella C van den Hout; Anne Marie de Man; Ilse Hageman; Susanne Bogers; C Ellen van der Schoot; Francis Swaneveld; Adam A Anas; Casper Rokx; Bart J A Rijnders

doi:10.1093/cid/ciab647

Effects of Treatment of Coronavirus Disease 2019 With Convalescent Plasma in 25 B-Cell-Depleted Patients

Clin Infect Dis. 2022 Apr 9;74(7):1271-1274. doi: 10.1093/cid/ciab647.

Authors

Arvind Gharbharan¹, Corine H GeurtsvanKessel², Carlijn C E Jordans¹, Marc Blaauw³, Marjolein van der Klift⁴, Robert-Jan Hassing⁵, Marijn Smits-Zwinkels⁶, Maaike Meertens⁷, Ella C van den Hout⁸, Anne Marie de Man⁹, Ilse Hageman¹⁰, Susanne Bogers², C Ellen van der Schoot¹¹, Francis Swaneveld¹², Adam A Anas¹, Casper Rokx¹, Bart J A Rijnders¹

Affiliations

¹ Department of Internal Medicine, Section of Infectious Diseases and Department of Medical Microbiology and Infectious Diseases, Erasmus Medical Center, University Medical Center, Rotterdam, The Netherlands.
² Department of Viroscience, Erasmus Medical Center, Rotterdam, The Netherlands.
³ Department of Internal Medicine, Elisabeth-Tweesteden Hospital, Tilburg, The Netherlands.
⁴ Department of Internal Medicine, Amphia Hospital, Breda, The Netherlands.
⁵ Department of Internal Medicine, Rijnstate Hospital, Arnhem, The Netherlands.
⁶ Department of Pulmonary Medicine, ZorgSaam Hospital, Terneuzen, The Netherlands.
⁷ Department of Intensive Care Medicine, Onze Lieve Vrouwe Gasthuis, Amsterdam, The Netherlands.
⁸ Department of Internal Medicine, Northwest Clinics, Alkmaar, The Netherlands.
⁹ Department of Internal Medicine, Elkerliek Ziekenhuis, Helmond, The Netherlands.
¹⁰ Department of Internal Medicine, Jeroen Bosch Hospital, den Bosch, The Netherlands.
¹¹ Department of Experimental Immunohematology, Sanquin Research, Amsterdam, The Netherlands.
¹² Unit of Transfusion Medicine, Sanquin Blood Supply, Amsterdam, The Netherlands.

Abstract

Twenty-five B-cell-depleted patients (24 following anti-CD19/20 therapy) diagnosed with coronavirus disease 2019 had been symptomatic for a median of 26 days but remained antibody negative. All were treated with convalescent plasma with high neutralizing antibody titers. Twenty-one (84%) recovered, indicating the potential therapeutic effects of this therapy in this particular population.

Trial registration: ClinicalTrials.gov NCT04375098.

Keywords: 19; 2; B; COVID; CoV; SARS; cell depletion; convalescent plasma; immunodeficiency.

MeSH terms

Antibodies, Neutralizing / therapeutic use
Antibodies, Viral
COVID-19 Serotherapy
COVID-19* / therapy
Humans
Immunization, Passive
SARS-CoV-2

Substances

Antibodies, Neutralizing
Antibodies, Viral

Associated data

ClinicalTrials.gov/NCT04375098